申请人:Purdue Pharma L.P.
公开号:US20150238485A1
公开(公告)日:2015-08-27
The present disclosure relates to Oxime-Substituted Quinoxaline-Type Piperidine Compounds, such as those of Formula (I):
and the pharmaceutically acceptable salts and solvates thereof, wherein R
1
, R
2
, R
3
, R
4
, R
20
, R
21
, Q, Y
1
, Z, A, B, and a are as defined herein; compositions comprising an effective amount of an Oxime-Substituted Quinoxaline-Type Piperidine Compound, and methods to treat or prevent a condition, such as pain, comprising administering to an animal in need thereof an effective amount of an Oxime-Substituted Quinoxaline-Type Piperidine Compound.
本公开涉及肟取代的喹噁啉型哌啶化合物,例如式(I)中的化合物及其药学上可接受的盐和溶剂化合物,其中R1、R2、R3、R4、R20、R21、Q、Y1、Z、A、B和a如本文所定义;包含有效量肟取代的喹噁啉型哌啶化合物的组合物,以及治疗或预防疾病(如疼痛)的方法,包括向需要治疗的动物中有效量的肟取代的喹噁啉型哌啶化合物。